CL2012001056A1 - Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. - Google Patents
Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.Info
- Publication number
- CL2012001056A1 CL2012001056A1 CL2012001056A CL2012001056A CL2012001056A1 CL 2012001056 A1 CL2012001056 A1 CL 2012001056A1 CL 2012001056 A CL2012001056 A CL 2012001056A CL 2012001056 A CL2012001056 A CL 2012001056A CL 2012001056 A1 CL2012001056 A1 CL 2012001056A1
- Authority
- CL
- Chile
- Prior art keywords
- tumors
- prevention
- pharmaceutical composition
- treatment
- asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
UN COMPUESTO DE FORMULA I DONDE R1, R2, R3 , R4, R5, R6 , R7, R8 , R9 Y N SE DEFINEN TAL COMO EN LA MEMORIA DESCRIPTIVA. UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN COMPUESTO DE FÓRMULA L A UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, EN ASOCIACIÓN CON UN DILUYENTE O VEHLCULO FARMACÉUTICAMENTE ACEPTABLE. USO DE UN COMPUESTO DE FÓRMULA I, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, EN LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL EN EL TRATAMIENTO O PREVENCIÓN DE TUMORES QUE SON SENSIBLES A LA INHIBICIÓN DE ENZIMAS PI 3-QUINASA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306017 | 2009-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012001056A1 true CL2012001056A1 (es) | 2012-10-05 |
Family
ID=43085922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001056A CL2012001056A1 (es) | 2009-10-27 | 2012-04-25 | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. |
Country Status (41)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| US8530470B2 (en) * | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| ES2608395T3 (es) | 2013-01-23 | 2017-04-10 | Astrazeneca Ab | Compuestos químicos |
| MX362905B (es) | 2013-03-04 | 2019-02-25 | Astrazeneca Ab | Tratamiento de combinacion. |
| CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| EA201692266A1 (ru) | 2014-06-13 | 2017-06-30 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
| NZ726608A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| MA40059A (fr) | 2014-06-13 | 2015-12-17 | Gilead Sciences Inc | Inhibiteurs de la phosphatidylinositol 3-kinase |
| NZ726052A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| WO2017060406A1 (en) * | 2015-10-09 | 2017-04-13 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20210141214A (ko) * | 2020-05-15 | 2021-11-23 | 제이투에이치바이오텍 (주) | 3원환 화합물 및 이의 의약 용도 |
| KR20240016938A (ko) * | 2021-02-01 | 2024-02-06 | 지오드 테라퓨틱스 인크. | 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법 |
| JP2024516993A (ja) * | 2021-05-03 | 2024-04-18 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 |
| CA3217937A1 (en) | 2021-05-03 | 2022-11-10 | Erin Danielle ANDERSON | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| US11878970B2 (en) | 2021-05-27 | 2024-01-23 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| WO2024081904A1 (en) * | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | Methods for treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6027A (en) * | 1849-01-09 | Rotary blacksmith s twyer | ||
| JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| ES2106783T3 (es) | 1990-06-20 | 1997-11-16 | Upjohn Co | 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas. |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
| CN1891699A (zh) | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
| CA2495661C (en) * | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| EP1957475A1 (en) | 2005-10-21 | 2008-08-20 | Merz Pharma GmbH & Co.KGaA | Chromenones and their use as modulators of metabotropic glutamate receptors |
| SI2004654T1 (sl) * | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2112145A1 (en) | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
| WO2010134082A1 (en) | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2010
- 2010-10-22 US US12/909,968 patent/US8399460B2/en active Active
- 2010-10-25 MX MX2012005027A patent/MX2012005027A/es active IP Right Grant
- 2010-10-25 AU AU2010311107A patent/AU2010311107B9/en active Active
- 2010-10-25 KR KR1020127012933A patent/KR101738195B1/ko active IP Right Grant
- 2010-10-25 PE PE2012000578A patent/PE20130149A1/es active IP Right Grant
- 2010-10-25 JP JP2012535931A patent/JP5657010B2/ja active Active
- 2010-10-25 EP EP10769052.1A patent/EP2493870B1/en active Active
- 2010-10-25 MY MYPI2012001831A patent/MY179833A/en unknown
- 2010-10-25 IN IN3328DEN2012 patent/IN2012DN03328A/en unknown
- 2010-10-25 BR BR112012010124A patent/BR112012010124B8/pt active IP Right Grant
- 2010-10-25 UA UAA201206000A patent/UA107474C2/uk unknown
- 2010-10-25 PL PL10769052T patent/PL2493870T3/pl unknown
- 2010-10-25 CA CA2776994A patent/CA2776994C/en active Active
- 2010-10-25 EA EA201200618A patent/EA020523B9/ru not_active IP Right Cessation
- 2010-10-25 WO PCT/GB2010/051788 patent/WO2011051704A1/en active Application Filing
- 2010-10-25 CN CN201410654983.0A patent/CN104447657B/zh active Active
- 2010-10-25 SI SI201030875T patent/SI2493870T1/sl unknown
- 2010-10-25 ES ES10769052T patent/ES2530943T3/es active Active
- 2010-10-25 CN CN201080060262.7A patent/CN102712615B/zh active Active
- 2010-10-25 ME MEP-2015-21A patent/ME02050B/me unknown
- 2010-10-25 NZ NZ599457A patent/NZ599457A/en not_active IP Right Cessation
- 2010-10-25 DK DK10769052.1T patent/DK2493870T3/en active
- 2010-10-25 RS RS20150090A patent/RS53813B1/en unknown
- 2010-10-25 PT PT10769052T patent/PT2493870E/pt unknown
- 2010-10-26 AR ARP100103937 patent/AR078786A1/es active IP Right Grant
- 2010-10-27 UY UY32978A patent/UY32978A/es not_active Application Discontinuation
- 2010-10-27 TW TW099136762A patent/TWI483939B/zh active
- 2010-10-27 SA SA110310808A patent/SA110310808B1/ar unknown
-
2012
- 2012-04-15 IL IL219191A patent/IL219191A0/en not_active IP Right Cessation
- 2012-04-25 CL CL2012001056A patent/CL2012001056A1/es unknown
- 2012-04-26 CO CO12068977A patent/CO6541528A2/es active IP Right Grant
- 2012-04-27 DO DO2012000124A patent/DOP2012000124A/es unknown
- 2012-04-27 EC ECSP12011838 patent/ECSP12011838A/es unknown
- 2012-04-27 CU CU2012000069A patent/CU20120069A7/es unknown
- 2012-04-27 GT GT201200126A patent/GT201200126A/es unknown
- 2012-04-27 HN HN2012000889A patent/HN2012000889A/es unknown
- 2012-04-27 NI NI201200081A patent/NI201200081A/es unknown
- 2012-04-27 CR CR20120217A patent/CR20120217A/es unknown
-
2013
- 2013-01-22 HK HK13100967.4A patent/HK1174027A1/xx unknown
- 2013-02-13 US US13/765,850 patent/US8673906B2/en active Active
-
2014
- 2014-01-24 US US14/163,105 patent/US9029374B2/en active Active
- 2014-11-20 JP JP2014235289A patent/JP5872016B2/ja active Active
-
2015
- 2015-02-05 HR HRP20150146TT patent/HRP20150146T1/hr unknown
- 2015-02-12 SM SM201500036T patent/SMT201500036B/xx unknown
- 2015-02-13 CY CY20151100157T patent/CY1116143T1/el unknown
- 2015-04-08 US US14/681,244 patent/US20160060240A1/en not_active Abandoned
- 2015-07-20 HK HK15106851.8A patent/HK1206335A1/zh unknown
-
2016
- 2016-03-24 US US15/079,633 patent/US9718800B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| DOP2012000225A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| EP3363797A8 (en) | Oral dosage form of apoptosis signal-regulating kinase inhibitors | |
| IN2012DN01233A (es) | ||
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| HK1138840A1 (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| MX348422B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| MX2013006083A (es) | Derivados de 6-amino-2-fenilamino-1h-bencimidazola-5-carboxamida y sus uso como inhibidores de prostaglandina e2 sintasa-1 microsomal. | |
| AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| EP2400847A4 (en) | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | |
| TN2010000038A1 (en) | Organic compounds | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| IN2012DN03182A (es) | ||
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
| CO6470899A2 (es) | 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal | |
| AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |